Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

All Drugs and Chemicals

Antineoplastic Agents

Antibodies

Paclitaxel

Albumin-Bound Paclitaxel

Immunoglobulins

Fruquintinib 4mg d1-14, q3w Paclitaxel 150mg/m2, d1, q3w / Albumin paclitaxel 125mg/m2, d1, d8, q3w PD-L1 antibody (Adebrelimab) 20 mg/kg, d1, q3w

Adebrelimab，Fruquintinib combined with chemotherapy

Adebrelimab，Fruquintinib

Ting Deng, MD

Jiayu Zhang, MD

This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib and Adebrelimab combined with paclitaxel/albumin paclitaxel for second-line treatment of advanced gastric cancer.

The benefits of immunotherapy in first-line treatment for gastric cancer patients whose tumor tissue CPS\<5 are limited. And some patients have not been treated by immunotherapy in the first-line treatment in clinical practice. This study intends to enroll first-line patients with advanced gastric cancer who have not been treated with PD-1 antibody, and explore the effectiveness and safety of second-line PD-L1 antibody combined with Fruquintinib and paclitaxel/albumin-paclitaxel, providing clues for the application of PD-L1 antibody in advanced gastric cancer.

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer

Phase II Clinical Study of Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Time from the start of treatment to the progression of the disease

Time from the start of treatment to the occurrence of death

Tianjin Medical University Cancer Institute and Hospital

Since the first-line ICIs application of gastric cancer is mainly PD-1 antibody, this study intends to screen first-line patients exposed to PD-1 antibody and with long survival (PFS longer than 9 months) to receive second-line PD-L1 antibody for re-challenge and combine with Fruquintinib and paclitaxel to explore whether it can further increase the effect of second-line treatment.

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed

Phase II Clinical Study of Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer After First-line Treatment With PD-1 Antibody Failed

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer	NCT06102772	Gastric Cancer	Adebrelimab，Fru...	18 Years -	Tianjin Medical University Cancer Institute and Hospital
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed	NCT06102759	Gastric Cancer	Adebrelimab，Fru...	18 Years -	Tianjin Medical University Cancer Institute and Hospital

Spots Global Cancer Trial Database for adebrelimab，fruquintinib